Low-intensity shockwave therapy for ED
Low-intensity shockwave therapy for ED explained: honest success rates, what a session involves, and what current evidence really shows.
Also known as: Li-ESWT, LiSWT, shockwave therapy for erectile dysfunction
✓ Clinician-reviewed information- Low-intensity shockwave therapy (Li-ESWT) is a non-invasive, outpatient treatment using low-energy acoustic pulses applied to the penis, with no anaesthesia, no incisions, and no recovery time.
- The best-supported use is for mild-to-moderate vasculogenic ED — reduced blood flow — not for severe ED, psychogenic ED, or ED with a significant neurological cause.
- A 2025 meta-analysis of 12 randomized trials found a real improvement over sham treatment, but a stricter 2025 Cochrane review found the overall evidence still too inconsistent in quality to state confidently how much it helps.
- In one study of men who had not responded to ED tablets, 71% achieved an erection firm enough for penetration by 16 weeks — encouraging, but from a single, modest-sized study.
- The treatment is very low-risk physically. The bigger honest risk is paying for a course whose benefit, per the most rigorous review, is not yet fully proven.
About low-intensity shockwave therapy for ed
Low-intensity shockwave therapy, often shortened to Li-ESWT, is a treatment for erectile dysfunction that uses gentle sound-wave pulses. A small probe is held against the skin of the penis. It sends low-energy pulses to a few set areas over about 15 to 20 minutes. There are no needles, no cuts, and no anaesthetic. Most men go straight back to normal activity afterward.
The idea behind it is different from pills like Viagra. Those pills boost blood flow at the moment you take them. They treat the symptom, on demand. Shockwave therapy aims to work on the tissue itself. The pulses are thought to create tiny, controlled stress in the tissue. This may trigger a healing response, with new small blood vessels forming over time. In theory, it improves the blood supply of the tissue, rather than just boosting flow for one occasion. That is why some clinics call it a way to treat the "root cause" of blood-flow-related ED.
It is important to be honest about how strong the proof is. The lab science behind the idea is reasonable. But turning that into a clearly proven benefit for real men is where the picture gets mixed. A 2025 pooled analysis of 12 trials, covering 882 men, found a real, measurable improvement over fake (sham) treatment. Yet a separate, very strict 2025 Cochrane review looked at all the evidence together. It found it too inconsistent in quality to say, with confidence, how much it truly helps. Both things are true at once: individual trials look encouraging, and the overall evidence is not yet fully settled.
So who is it for? The best-supported use is mild-to-moderate ED caused by poor blood flow. It is also studied in men who did not respond well to ED pills. In one study of such men, 71% reached an erection firm enough for sex by 16 weeks. That is encouraging, though it comes from a single, modest-sized study. It is not a good fit for ED that is mainly psychological, or caused by nerve damage.
The treatment itself is very low-risk. The bigger, more honest risk is a different kind: paying for a course whose benefit is not fully proven. Protocols also vary between clinics, which is itself a weakness in the evidence. Most strong studies used sessions spread over several weeks. Some clinics offer shorter, daily courses for travelling patients. That is reasonable, but less directly studied. It is worth asking your clinic exactly which protocol they use, and how it compares to what the research actually tested.
Both things can be true at once: individual trials show real promise, and the overall evidence base, judged rigorously as a whole, is not yet as settled as a fully "proven" treatment would be.
Who it is for
- •Men with mild-to-moderate ED confirmed or strongly suspected to be vasculogenic (blood-flow related)
- •Men who respond to ED tablets but would prefer to explore a non-pharmacological option
- •Men whose ED has not responded adequately to ED tablets, where some studies show a meaningful proportion can still benefit
- •Men seeking a low-risk, non-invasive option before considering injections or a penile implant
- •Men whose ED is primarily psychogenic (psychological), without a significant vascular component
- •Men with significant neurogenic ED, including from spinal cord injury or multiple sclerosis
- •Men with cardiac or other implanted electrical devices (commonly an exclusion criterion in trials)
- •Men seeking a guaranteed, rapid fix rather than a course of treatment with a realistic, not guaranteed, chance of benefit
Preparing for surgery
What recovery looks like
Risks and complications
Common questions
Does shockwave therapy actually cure erectile dysfunction?
How many sessions will I need?
Is this the same as the shockwave therapy used for sports injuries?
Can I combine shockwave therapy with Viagra or Cialis?
I have already tried the tablets and they did not work well — is this still worth considering?
Is shockwave therapy painful?
Why do some clinics claim very high success rates when the Cochrane review is cautious?
Can shockwave therapy make my ED worse?
How long does any improvement last?
If it does not work, have I lost the chance to try other treatments?
Patient reviews
Been treated? Your honest review of Low-intensity shockwave therapy for ED helps the next patient.
Be the first to share your experience of this procedure. We read and verify every review before it is published.
Write the first reviewSources
- Sokolakis I, et al. Efficacy of low-intensity shock wave therapy for erectile dysfunction: updated meta-analysis of randomized trials. 2025. https://www.tandfonline.com/doi/full/10.1080/20565623.2025.2511438
- Low-intensity shockwave therapy for erectile dysfunction. Cochrane Database Syst Rev. 2025 Jul 14;7(7):CD013166. https://pubmed.ncbi.nlm.nih.gov/40654049/
- Chung E, Cartmill R. Low intensity extracorporeal shockwave therapy shifts PDE5i nonresponders to responders. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527091/
- The recommended treatment protocol for low-intensity shockwave therapy based on the severity of ED. Int J Impot Res. 2024. https://www.nature.com/articles/s41443-024-00959-7
- Long-term effectiveness and predictors of success of low-intensity shockwave therapy in PDE5i non-responders. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006645/
